Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Income (2017 - 2025)

Protagonist Therapeutics' Net Income history spans 9 years, with the latest figure at -$44.8 million for Q4 2025.

  • For Q4 2025, Net Income fell 134.06% year-over-year to -$44.8 million; the TTM value through Dec 2025 reached -$130.6 million, down 147.47%, while the annual FY2025 figure was -$130.6 million, 147.47% down from the prior year.
  • Net Income for Q4 2025 was -$44.8 million at Protagonist Therapeutics, down from -$39.3 million in the prior quarter.
  • Across five years, Net Income topped out at $207.4 million in Q1 2024 and bottomed at -$44.8 million in Q4 2025.
  • The 5-year median for Net Income is -$32.2 million (2022), against an average of -$3.0 million.
  • The largest annual shift saw Net Income tumbled 335.17% in 2021 before it surged 714.87% in 2024.
  • A 5-year view of Net Income shows it stood at $88.9 million in 2021, then tumbled by 138.55% to -$34.3 million in 2022, then skyrocketed by 186.13% to $29.5 million in 2023, then surged by 346.08% to $131.6 million in 2024, then tumbled by 134.06% to -$44.8 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Net Income are -$44.8 million (Q4 2025), -$39.3 million (Q3 2025), and -$34.8 million (Q2 2025).